A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets
globalreutersSeptember 8, 20241 Mins read 
NeOnc Technologies is preparing to go public via the less common path of a direct listing as it continues mid-stage testing of its intranasally administered brain cancer drug. Meanwhile, the mostly stagnant biotech IPO pipeline is showing new signs of life with two large stock market debuts expected this week.
The post A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets appeared first on MedCity News.
Related Articles
Links
Hatch Waxman turns 40. FDA: Integrating RCT into routine clinical practice. Cost...
What Are the Challenges in Building a Consumer-Focused Diagnostic Testing Startup?
During a panel discussion at the MedCity News INVEST Digital Health Conference,...
BREAKING: FG Moves To Decriminalise Suicide Attempts
FG has moved to decriminalise suicide attempts. NewsOnline Nigeria reports that...
New XEC Covid variant: What are the symptoms and is it spreading in the UK?
The Covid-19 pandemic is constantly changing, with new variants appearing occasionally. Lately,...
Leave a comment